Pharma · Private company
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Track this companyFree. Adds Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany to your Dealase workspace and tells you when its record changes.
Clinical trials139 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- Cladribine High DosePhase 3 · Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- Cladribine Low DosePhase 3 · Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- EvobrutinibPhase 3 · Relapsing Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- TeriflunomidePhase 3 · Relapsing Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- M5049 high dosePhase 2 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
- M5049 low dosePhase 2 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
- M5049 medium dosePhase 2 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials13
- A Study of Mirdametinib in People With Central Nervous System TumorsPHASE1_PHASE2 · RECRUITING · started Apr 10, 2026ClinicalTrials.gov NCT07539441 · fetched Nov 12, 2026
- A Study of Mirdametinib in Combination With Palbociclib in People With LiposarcomaPHASE1_PHASE2 · RECRUITING · started Feb 19, 2025ClinicalTrials.gov NCT06843967 · fetched Nov 12, 2026
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 29, 2025ClinicalTrials.gov NCT06710132 · fetched Nov 12, 2026
- Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical StudyPHASE2 · RECRUITING · started Nov 26, 2024ClinicalTrials.gov NCT05879146 · fetched Nov 12, 2026
- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)PHASE3 · RECRUITING · started Jun 25, 2024ClinicalTrials.gov NCT06463587 · fetched Nov 12, 2026
- Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).PHASE1_PHASE2 · RECRUITING · started Feb 12, 2024ClinicalTrials.gov NCT06159166 · fetched Nov 12, 2026
- Study of Cryoablation and Nirogacestat for Desmoid TumorPHASE2 · RECRUITING · started Aug 15, 2023ClinicalTrials.gov NCT05949099 · fetched Nov 12, 2026
- The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 16, 2022ClinicalTrials.gov NCT05540327 · fetched Nov 12, 2026
- SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade GliomaPHASE1_PHASE2 · RECRUITING · started Jun 21, 2021ClinicalTrials.gov NCT04923126 · fetched Nov 12, 2026
- Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast CancerPHASE2 · TERMINATED · started Oct 12, 2020ClinicalTrials.gov NCT04489940 · fetched Nov 12, 2026
- Study of Evobrutinib in Participants With RMS (evolutionRMS 2)PHASE3 · TERMINATED · started Jul 2, 2020ClinicalTrials.gov NCT04338061 · fetched Nov 12, 2026
- Study of Evobrutinib in Participants With RMS (evolutionRMS 1)PHASE3 · TERMINATED · started Jun 12, 2020ClinicalTrials.gov NCT04338022 · fetched Nov 12, 2026
- Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid TumorsPHASE1 · COMPLETED · started May 1, 2019ClinicalTrials.gov NCT03905148 · fetched Nov 12, 2026